Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rangering i aksjer #25853
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Aksjekurs
$15.31
Sist synkronisert: 2024-02-29
Markedsverdi
$45.70M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Icosavax, Inc. (ICVX)

Kategori

Aksjeprishistorikk for Icosavax, Inc. (ICVX)
Høyeste sluttskurs: $15.31 den 2024-02-01

Laveste sluttskurs: $29.91 den 2021-07-01
Aksjeprishistorikk for Icosavax, Inc. fra 2021 til 2026
Årlig aksjeprisytelse
År Ytelse
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US